The latest market report published by Credence Research, Inc. “Painful Diabetic Neuropathy Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026” the painful diabetic neuropathy drugs market was valued at US$ 4,811.8 Mn in 2017 and expected to reach US$ 8,962.0 Mn by 2026, expanding at a CAGR of 6.6 % from 2018 to 2026.
Browse the full report Painful Diabetic Neuropathy Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at http://www.credenceresearch.com/report/painful-diabetic-neuropathy-drugs-market
Global painful diabetic neuropathy drugs (PDN) market accounted to a market value of US$ 4,811.8 Mn in 2017 and projected to attain value of US$ 8,962.0 Mn by 2026 at a CAGR of 6.6% during the forecast period. The growth of this market primarily driven by the ever-growing pool of geriatric population with diabetes. The rise in availability of suitable treatment options and the growing awareness on PDN catalyzes the demand for PDN drugs. With only four drugs currently approved for the management of PDN (Lyrica, Cymbalta, Nucynta and Qutenza), there arises a huge opportunity for new and emerging market players with potential pipeline portfolio. Of the marketed products analyzed, Lyrica accounted for a maximum market share in 2017 and will continue similar trend through 2026. The recent approval of Lyrica’s control release formulation in October 2017 further augments its market growth. The PDN drugs market observes a presence of strong pipeline portfolio, which would facilitate the overall growth during the forecast period from 2018 to 2026. ViroMed Co. Ltd.’s VM202 currently in phase III is the only gene therapy developed with disease modifying properties. However, the higher pricing of gene therapy could hamper the growth of VM202 in the near future.
Other players with potential product portfolio includes Pfizer, Inc., Grunenthal GmbH, Daiichi-Sankyo Company Limited, ViroMed Co. Ltd., Collegium Pharmaceutical, Inc., Acorda Therapeutics, Inc., Zydus Pharmaceuticals USA, Inc., Mallinckrodt, Inc., and Macleods Pharmaceuticals Ltd.
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I – Secondary Research
1.4.2. Phase II – Primary Research
1.4.3. Phase III – Expert Panel Review
Chapter 2. Executive Summary
2.1. Global Painful Diabetic Neuropathy Drugs Market Portraiture
2.2. Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2017 (US$ Mn)
2.3. Painful Diabetic Neuropathy Drugs Market, by Geography, 2017 (US$ Mn)
Chapter 3. Global Painful Diabetic Neuropathy Drugs Market: Dynamics and Future Outlook
3.2. Market Dynamics
3.2.1. Market Drivers
18.104.22.168. Increased Prevalence of Diabetes
22.214.171.124. Continuous Research Activities
3.2.2. Market Challenges
126.96.36.199. Challenge 1 …
Chapter 6. Profiles
6.1. Pfizer, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Grunenthal GmbH
6.3. Daiichi-Sankyo Company Limited
6.4. ViroMed Co. Ltd.
6.5. Collegium Pharmaceutical, Inc.
6.6. Eli Lilly and Company …
Download sample research report @ http://www.credenceresearch.com/sample-request/59180
Lyrica Gained Maximum Market Share and will Continue with Similar Trends during the Forecast Period
Based on drug type, Lyrica accounted for highest market share of above 26% in 2017 and will continue its dominance throughout the forecast period from 2018 to 2026. Lyrica is the only marketed drug that has gained marketing approval from Food and Drug Administration (FDA) of U.S., European Medical Agency (EMA) and Pharmaceutical & Medical Device Agency (PMDA) of Japan. Lyrica is also recommended as the first line of therapy by America Diabetes Association to treat PDN. These factors make Lyrica a dominant contributor to the overall growth of the market. Additionally, recent approval of Lyrica CR (October 2017) by U.S FDA ensures remunerative growth of this market segment. Qutenza accounts for fastest CAGR during the forecast period from 2018 to 2026. Qutenza is approved so far only in Europe; further marketing approval across geographies and its formulation as an adhesive patch would increase the demand for the same upon approval. Qutenza comprises minimal patient discomfort when compared to the daily dosing therapeutic agents thus projected to gain market attraction. However, the market share of existing approved products could be hampered by the penetration of pipeline molecules with target-based therapy.
North America Demonstrated Supremacy in 2017 and will Maintain its Dominancy Through 2026
North America accounted for major market share of more than 55% in 2017 and projected to continue the trend throughout the forecast period. Increased prevalence of diabetes and diabetes-associated complications primarily drive the market growth in this region. Rapid commercialization of novel drugs and the continuous investment by local manufacturers in developing target-based therapy further catalyzes the market growth. According to the Centers for Disease Control and Prevention (CDC), around 30.3 million individuals of all ages suffered from diabetes in 2015 in the U.S. This high prevalence of diabetes further increases the risk for painful diabetic neuropathy thus indicating potential market growth. Asia Pacific will exhibit fastest CAGR during the forecast period from 2018 to 2026. Growing awareness on diabetes-associated complications, availability of newer products and investment by international players contributes to the growth in this region.
Related Reports :
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Company Name: Credence Research, Inc
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Address:105 N 1st ST #429, SAN JOSE, CA 95103 US
City: SAN JOSE
Country: United States